## Jie Xia

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6973206/publications.pdf

Version: 2024-02-01

|                | 687363       | 642732                          |
|----------------|--------------|---------------------------------|
| 599            | 13           | 23                              |
| citations      | h-index      | 23<br>g-index                   |
|                |              |                                 |
|                |              |                                 |
|                |              |                                 |
| 30             | 30           | 959                             |
| docs citations | times ranked | citing authors                  |
|                |              |                                 |
|                | citations 30 | 599 13 citations h-index  30 30 |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Advances in GPCR Modeling Evaluated by the GPCR Dock 2013 Assessment: Meeting New Challenges. Structure, 2014, 22, 1120-1139.   | 3.3 | 149       |
| 2  | An Unbiased Method To Build Benchmarking Sets for Ligand-Based Virtual Screening and its Application To GPCRs. Journal of Chemical Information and Modeling, 2014, 54, 1433-1450.   | 5.4 | 46        |
| 3  | Benchmarking methods and data sets for ligand enrichment assessment in virtual screening. Methods, 2015, 71, 146-157.   | 3.8 | 40        |
| 4  | N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: Design, synthesis, biological evaluation and target identification. European Journal of Medicinal Chemistry, 2020, 188, 112022.            | 5.5 | 36        |
| 5  | Discovery of novel isoflavone derivatives as AChE/BuChE dual-targeted inhibitors: synthesis, biological evaluation and molecular modelling. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 968-977.                                      | 5.2 | 32        |
| 6  | Mechanism-based design, synthesis and biological studies of N5-substituted tetrahydrofolate analogs as inhibitors of cobalamin-dependent methionine synthase and potential anticancer agents. European Journal of Medicinal Chemistry, 2012, 58, 228-236. | 5.5 | 27        |
| 7  | Comparative Modeling and Benchmarking Data Sets for Human Histone Deacetylases and Sirtuin Families. Journal of Chemical Information and Modeling, 2015, 55, 374-388.   | 5.4 | 25        |
| 8  | Synthesis and biological activity evaluation of 20-epi-salinomycin and its 20-O-acyl derivatives. RSC Advances, 2016, 6, 41885-41890.   | 3.6 | 23        |
| 9  | Design, Synthesis and Biological Evaluation of Noncovalent Inhibitors of Human CD38 NADase.<br>ChemMedChem, 2012, 7, 223-228.   | 3.2 | 21        |
| 10 | Study on pharmacokinetics and tissue distribution of single dose oral tryptanthrin in Kunming mice by validated reversed-phase high-performance liquid chromatography with ultraviolet detection. Integrative Medicine Research, 2017, 6, 269-279.        | 1.8 | 16        |
| 11 | Screening of cytochrome P450 3A4 inhibitors <i>via in silico</i> and <i>in vitro</i> approaches. RSC Advances, 2018, 8, 34783-34792.  | 3.6 | 16        |
| 12 | HDAC3iâ€Finder: A Machine Learningâ€based Computational Tool to Screen for HDAC3 Inhibitors. Molecular Informatics, 2021, 40, e2000105.   | 2.5 | 16        |
| 13 | The discovery of novel HDAC3 inhibitors via virtual screening and <i>in vitro</i> bioassay. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 525-535.  | 5.2 | 15        |
| 14 | Design and synthesis of conformationally constrained salinomycin derivatives. European Journal of Medicinal Chemistry, 2017, 138, 353-356.  | 5.5 | 14        |
| 15 | Discovery of potent PTP1B inhibitors via structure-based drug design, synthesis and in vitro bioassay of Norathyriol derivatives. Bioorganic Chemistry, 2019, 86, 224-234.  | 4.1 | 13        |
| 16 | Enrichment Assessment of Multiple Virtual Screening Strategies for Tollâ€Like Receptor 8 Agonists<br>Based on a Maximal Unbiased Benchmarking Data Set. Chemical Biology and Drug Design, 2015, 86,<br>1226-1241.   | 3.2 | 11        |
| 17 | Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors.<br>Molecules, 2017, 22, 1029.   | 3.8 | 11        |
| 18 | The Development of Target-Specific Pose Filter Ensembles To Boost Ligand Enrichment for Structure-Based Virtual Screening. Journal of Chemical Information and Modeling, 2017, 57, 1414-1425.   | 5.4 | 10        |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | MUBDâ€DecoyMaker 2.0: A Python GUI Application to Generate Maximal Unbiased Benchmarking Data Sets for Virtual Drug Screening. Molecular Informatics, 2020, 39, e1900151.   | 2.5 | 10        |
| 20 | Computational representations of protein–ligand interfaces for structure-based virtual screening. Expert Opinion on Drug Discovery, 2021, 16, 1175-1192.  | 5.0 | 10        |
| 21 | Bacterial Lipoprotein Biosynthetic Pathway as a Potential Target for Structure-based Design of Antibacterial Agents. Current Medicinal Chemistry, 2020, 27, 1132-1150.  | 2.4 | 10        |
| 22 | A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors. International Journal of Molecular Sciences, 2017, 18, 137.  | 4.1 | 8         |
| 23 | Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression. Cell Death and Disease, 2022, 13, 388.   | 6.3 | 8         |
| 24 | Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists. Journal of Chemical Information and Modeling, 2020, 60, 1202-1214.  | 5.4 | 7         |
| 25 | Discovery of <i>N &lt; /i&gt; -quinazolinone-4-hydroxy-2-quinolone-3-carboxamides as DNA gyrase B-targeted antibacterial agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1620-1631.</i>   | 5.2 | 6         |
| 26 | Histone deacetylase 3-selective inhibitor RGFP966 ameliorates impaired glucose tolerance through $\hat{l}^2$ -cell protection. Toxicology and Applied Pharmacology, 2020, 406, 115189.  | 2.8 | 5         |
| 27 | Maximal Unbiased Benchmarking Data Sets for Human Chemokine Receptors and Comparative Analysis.<br>Journal of Chemical Information and Modeling, 2018, 58, 1104-1120.   | 5.4 | 4         |
| 28 | Anti-MRSA drug discovery by ligand-based virtual screening and biological evaluation. Bioorganic Chemistry, 2021, 114, 105042.  | 4.1 | 4         |
| 29 | A unique ligandâ€steered strategy for CC chemokine receptor 2 homology modeling to facilitate structureâ€based virtual screening. Chemical Biology and Drug Design, 2021, 97, 944-961.  | 3.2 | 3         |
| 30 | Serum Pharmacochemistry Combining Network Pharmacology to Discover the Active Constituents and Effect of Xijiao Dihuang Tang Prescription for Treatment of Blood-Heat and Blood-Stasis Syndrome-Related Disease. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-25. | 4.0 | 3         |